D.O. Zagvozkina
Research Subjects
D.O. Zagvozkina has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- A. G. Kudaybergenova
N.N. Petrov National Medical Research Center of Oncology, Ministry of Health of Russia
1 shared publication - Anna Yu. Shamanova
Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine
1 shared publication - Dmitry A. Tsekatunov
Regional Clinical Oncology Center
1 shared publication - Grigoriy Aleksandrovich Raskin
Saint Petersburg State University
1 shared publication - Iryna Shaposhnykova
Voronezh Regional Pathological Anatomy Bureau
1 shared publication - Ksenya V. Shelekhova
Clinical Research and Practical Center for Specialized Oncological Care, Saint Petersburg, Russia
1 shared publication
Latest Publications
- 18 June 2026
- Published by Media Sphere Publishing Group in Russian Journal of Archive of Pathology
- Vol. 88 (3) , 79-84
Assessment methodology of pathomorphological regression of melanoma metastasis in the sentinel lymph node after neoadjuvant/perioperative immunotherapy
This methodology has been developed to standardize the pathology evaluation of melanoma metastasis regression in the sentinel lymph node after neoadjuvant/perioperative immunotherapy in patients with stage III resectable cutaneous melanoma. The methodology is intended for use by pathologists, clinical and surgical oncologists, and healthcare quality assessment experts. It can be implemented as a local protocol for pathological examination, as well as integrated into national clinical guidelines and relevant organizational and methodological documents.
- 18 June 2026
- Published by Media Sphere Publishing Group in Russian Journal of Archive of Pathology
- Vol. 88 (3) , 79-84
Assessment methodology of pathomorphological regression of melanoma metastasis in the sentinel lymph node after neoadjuvant/perioperative immunotherapy
This methodology has been developed to standardize the pathology evaluation of melanoma metastasis regression in the sentinel lymph node after neoadjuvant/perioperative immunotherapy in patients with stage III resectable cutaneous melanoma. The methodology is intended for use by pathologists, clinical and surgical oncologists, and healthcare quality assessment experts. It can be implemented as a local protocol for pathological examination, as well as integrated into national clinical guidelines and relevant organizational and methodological documents.